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T-cell receptors (TCRs) have emerged as a new class of therapeutics, most prominently for 
cancer where they are the key components of new cellular therapies as well as soluble biologics. 
Many studies have generated high affinity TCRs in order to enhance sensitivity. Recent 
outcomes, however, have suggested that fine manipulation of TCR binding, with an emphasis on 
specificity may be more valuable than large affinity increments. Structure-guided design is 
ideally suited for this role, and here we studied the generality of structure-guided design as 
applied to TCRs. We found that a previous approach, which successfully optimized the binding 
of a therapeutic TCR, had poor accuracy when applied to a broader set of TCR interfaces. We 
thus sought to develop a more general purpose TCR design framework. After assembling a large 
dataset of experimental data spanning multiple interfaces, we trained a new scoring function that 
accounted for unique features of each interface. Together with other improvements, such as 
explicit inclusion of molecular flexibility, this permitted the design new affinity-enhancing 
mutations in multiple TCRs, including those not used in training. Our approach also captured the 
impacts of mutations and substitutions in the peptide/MHC ligand, and recapitulated recent 
findings regarding TCR specificity, indicating utility in more general mutational scanning of 
TCR–pMHC interfaces. 
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Introduction 
αβ T cells utilize clonotypic T-cell receptors (TCRs) to recognize antigens and initiate cellular 
immune responses. TCRs have emerged as a new class of therapeutics, most prominently for the 
treatment of cancer. Although in many ways similar to antibodies, TCRs differ in the complexity 
of the receptor-ligand interface: whereas antibodies can be elicited to almost any antigen, TCRs 
are restricted to linear peptide antigens presented by class I or class II MHC proteins (pMHC), 
with the TCR invariably contacting both (Rossjohn et al., 2015). Additionally, TCRs do not 
undergo affinity maturation, and, similar to naive antibodies, bind with weak-to-moderate 
affinities and reduced specificity (Baker et al., 2012). 
Recent advances have highlighted the potential therapeutic uses for TCRs with altered binding 
properties. As T-cell potency can be improved with antigen affinity (Varela-Rohena et al., 2008; 
Zhao et al., 2007), clinical trials with gene-modified T cells have explored the use of engineered, 
high affinity TCRs for improved antigen targeting (Linette et al., 2013). High affinity TCRs are 
also used as the antigen recognition component of soluble reagents designed to redirect naive, 
unmodified T cells (Oates and Jakobsen, 2013). 
Multiple methods have been used to generate high affinity TCRs, with the majority created using 
yeast or phage display (Bowerman et al., 2009; Holler et al., 2000; Li et al., 2005; Varela-
Rohena et al., 2008; Zhao et al., 2007). However, recent findings have shown that careful control 
is necessary when modifying TCRs. Due to their cross-reactive nature, enhancing affinity may 
introduce new reactivities: improving affinity against one antigen can improve affinity towards 
others, leading to reactivity towards antigens that might otherwise be ignored by T cells 
expressing the wild-type receptor. This could include self-antigens, leading to possible off-target 
recognition (Zhao et al., 2007). Such an outcome is believed to have led to fatal autoimmunity in 
a recent clinical trial that used a high affinity TCR to target a melanoma antigen (Linette et al., 
2013). The likelihood of such an outcome may be increased if added ‘glue’ is directed more 
towards the MHC protein than the peptide. Additionally, the relationship between TCR affinity 
and potency is not well understood. Although some very high affinity TCRs show considerable 
sensitivity (Varela-Rohena et al., 2008), in other cases improving affinity outside an optimal 
window or above a threshold has led to decreased potency (Stone and Kranz, 2013). 
Although in vitro evolution has been used to generate the majority of high affinity TCRs, 
structure-guided computational design offers the potential for finer control over affinity and 
specificity. Not only can interactions be manipulated in a way that more appropriately addresses 
peptide specificity, affinity increments can in principle be more tightly controlled. Towards these 
goals, structure-guided design has been used to modify a small number of TCRs (Haidar et al., 
2009; Malecek et al., 2014; Pierce et al., 2014; Zoete et al., 2013). Recently, we used structure-
guided design to engineer variants of the DMF5 TCR, which has been used clinically in 
immunotherapy for melanoma and continues to serve as a model TCR for improving cancer 
immunotherapy (Johnson et al., 2009). Building on an approach originally developed for the 
well-studied A6 TCR (Haidar et al., 2009), we successfully engineered nanomolar affinity 
variants of DMF5 with altered specificity, and found excellent agreement between prediction and 
experiment for both structure and affinity (Pierce et al., 2014). 
Here we addressed the generality of our TCR design efforts. We found that our approach 
successfully used with DMF5 performed poorly with additional mutations and other, unrelated 
TCRs. This may be attributable to the complexity of TCRs and their interfaces with pMHC, such 
as varying binding geometries, sub-optimal packing and differing amounts of receptor and ligand 
flexibility (Baker et al., 2012, Rossjohn et al., 2015). We therefore sought to develop a more 
generalizable framework for TCR design. After assembling and modeling a large training set of 
experimental binding data spanning multiple TCR–pMHC systems, we trained a candidate score 
function which outperformed those used previously. Performance was further enhanced by 
optimizing the scoring methodology and including information on receptor/ligand flexibility as 
well as buried water. This allowed for successful design of new, affinity-enhancing mutations in 
multiple TCRs, including an unrelated receptor not used in training. The new design framework 
was also successful in recapitulating positive and negative effects of mutations to the MHC 
protein as well as substitutions in the peptide, and captured emerging themes in TCR specificity 
(Adams et al., 2016). Although there are avenues for improvement, these new developments 
greatly extend the applicability of structure-guided design for the manipulation and screening of 
TCR binding properties, and suggest ways for computational screening for peptide antigenicity. 
 
Materials and Methods 
Crystal structure processing and design parameters 
For structural modeling, Rosetta with the Talaris2013 score function was used (Das and Baker, 
2008; Kaufmann et al., 2010; Leaver-Fay et al., 2013; Moretti et al., 2013), using the PyRosetta 
interface (Chaudhury et al., 2010). Native crystal structures were brought to local energy minima 
through multiple cycles of backbone minimization and rotamer optimization with heavy atom 
restraints (Bradley et al., 2005). Following structure minimization, the desired TCR, MHC, or 
peptide mutation was computationally introduced followed by three independent Monte Carlo 
based simulated annealing trajectories of the TCR CDR loops. This was performed using 
Rosetta's LoopMover_Refine_CCD mover with 3 outer cycles and 10 inner cycles, using an 
initial metropolis acceptance criteria of 2.2 that decreased linearly to 0.6 (Canutescu and 
Dunbrack, 2003). The large number of resulting packing operations introduced some minor 
variability when scoring the models. Therefore, the unweighted score terms for the three 
trajectories were averaged and stored for point mutation energy calculations (Kellogg et al., 
2011). When screening TCR point mutations, TCR residue positions with a center of mass within 
10 Å (DMF5 and B7) or 15 Å (DMF4) of a peptide heavy atom were selected for design. For 
peptide screens, all positions other than the primary anchors of the MART126(27L)–35 peptide 
underwent the design procedure. The design process sampled every amino acid (19 mutations 
and the wild-type residue) at each specified position in triplicate. Wild-type complexes were 
modeled and included in scoring to account for impacts of minimization and conformational 
sampling. For double mutants, both mutations were introduced simultaneously followed by a 
minimum of six independent minimization trajectories to account for additional structural 
impacts. 
Score function training 
To develop a new score function for predicting changes in binding ΔΔG°, we considered Rosetta 
full atom terms in addition to dynamically derived terms (bound and free order parameters and 
RMS fluctuations). Multiple linear regression was performed in MATLAB 2015b using 
measured ΔΔG° values. A stepwise elimination protocol was used to remove contextually 
insignificant terms. A k-fold (k = 10) cross validation was performed with the data points and 
significant predictor terms (Arlot and Celisse, 2010). 
Modeling explicit water molecules and sarcosine 
To model and score buried water molecules and the non-standard sarcosine, explicit TIP3P 
waters and sarcosine parameters were enabled in Rosetta. Water molecules were placed at their 
initial crystallographic coordinates followed by 100 high resolution docking trials to coordinate 
the water molecule in the pocket of the interfaces. The water coordinates were then fixed in 
position relative to the pMHC for TCR point mutation modeling. 
Molecular dynamics simulations of bound and free structures 
Molecular dynamics simulations were calculated utilizing the AMBER molecular dynamics suite 
(Salomon-Ferrer et al., 2013) as previously described (Ayres et al., 2016). Results for the free 
and bound A6 and DMF5 were taken from these simulations, with other simulations following 
the same protocol. Briefly, coordinates for the complexes with the LC13, B7 and DMF4 TCRs 
were obtained from PDB accession codes 1MI5, 1BD2 and 3QDM. Coordinates for the free 
Tax11–19/HLA-A2 complex were from 1DUZ. For the LC13, B7 and DMF4 TCRs, coordinates 
for the free TCRs were obtained by stripping away the pMHC. Prior to simulation, starting 
systems were charge neutralized with explicit Na+ counterions and solvated with explicit SPC/E 
water. Following this, systems were energy minimized and heated to 300 K with solute 
restraints. Afterwards, solute restraints were gradually relaxed and followed with 2 ns of 
simulation with no solute restraints for equilibration, after which 100 ns production trajectories 
for all systems were calculated. Trajectories were calculated using GPU-accelerated code (Götz 
et al., 2012; Salomon-Ferrer et al., 2013). Trajectory analysis including calculation of RMSF 
values used the ccptraj from the AMBER suite (Roe and Cheatham, 2013). Order parameters 
were calculated using isotropic reorientational eigenmode dynamic analysis using vectors 
defined from the Cα to Cβ (or Cα to H for glycine) atoms (Prompers and Brüschweiler, 2002). 
For double mutants, descriptors were averaged between the two positions for scoring purposes 
(i.e. for mutant XY, the RMSF of position X is averaged with the position Y RMSF to give an 
RMSF descriptor for XY). 
Protein expression and purification 
Expression and refolding of soluble constructs of the DMF5, B7 and DMF4 TCRs and HLA-A2 
were performed as previously described (Davis-Harrison et al., 2005). Briefly, the TCR α and β 
chains, the HLA-A2 heavy chain and β2-microglobulin (β2m) were generated in Escherichia coli 
as inclusion bodies, which were isolated and denatured in 8 M urea. TCR α and β chains were 
diluted in TCR refolding buffer (50 mM Tris (pH 8), 2 mM EDTA, 2.5 M urea, 9.6 mM 
cysteamine, 5.5 mM cystamine, 0.2 mM PMSF) at a 1:1 ratio. HLA-A2 and β2m were diluted in 
MHC refolding buffer (100 mM Tris (pH 8), 2 mM EDTA, 400 mM l-arginine, 6.3 mM 
cysteamine, 3.7 mM cystamine, 0.2 mM PMSF) at a 1:1 ratio in the presence of excess peptide. 
TCR and pMHC complexes were incubated for 24 h at 4°C. Afterward, complexes were desalted 
by dialysis at 4°C and room temperature respectively, then purified by anion exchange followed 
by size-exclusion chromatography. Refolded protein absorptions at 280 nm were measured 
spectroscopically and concentrations determined with appropriate extinction coefficients. 
Mutations in TCR α and β chains were generated by whole-plasmid mutagenesis and confirmed 
by sequencing. Peptides were synthesized and purified commercially. 
Surface plasmon resonance 
Surface plasmon resonance experiments were performed with a Biacore 3000 instrument using 
CM5 sensor chips as previously described (Davis-Harrison et al., 2005). In all experiments, TCR 
was immobilized to the sensor chip via standard amine coupling and pMHC complex was 
injected as analyte. Experiments were performed at 25°C in 20 mM HEPES (pH 7.4), 150 mM 
NaCl, 0.005% Nonidet P-20. All experiments were steady-state experiments measuring RU vs. 
concentration of injected analyte, and were performed with TCRs coupled onto the sensor chip at 
400–2000 response units. Injected pMHC spanned a concentration range of 0.1–150 μM at flow 
rates of 5 µl/min. Data were processed with BiaEvaluation 4.1 and fit using a 1:1 binding model 
utilizing MATLAB 2015b. 
 
Results 
Application of earlier structure-guided design methods to the B7 TCR 
Based on previous work with the A6 TCR (Haidar et al., 2009), we recently described a 
modeling and scoring scheme to predict the structural and energetic effects of point mutations 
within interfaces with the αβ TCR DMF5 (Pierce et al., 2014). Using this approach we identified 
several affinity-enhancing mutations in DMF5 which when combined led to affinity 
enhancements towards pMHC of up to 400-fold. To explore the generality of this approach, we 
applied the same methodology to the B7 TCR (Ding et al., 1998), which binds the human T-cell 
lymphoma virus Tax11–19 peptide presented by HLA-A2 with a similar affinity and orientation as 
the A6 TCR (Fig. (Fig.1a).1a). The A6 and B7 TCRs also share the same germline-derived Vβ 
chain, although crystallographic structures and biophysical studies of A6 and B7 with Tax11–
19/HLA-A2 showed structural and thermodynamic differences in binding (Davis-Harrison et al., 
2005). We modeled 740 point mutations in the B7-Tax11–19/HLA-A2 interface using Rosetta 
(Das and Baker, 2008; Kaufmann et al., 2010) and the scheme described in Pierce et al. (2014). 
As performed previously, effects were determined by scoring the complex, then separating the 
components and separately scoring the TCR and pMHC in order to calculate a ‘binding score’ 
(Kortemme and Baker, 2002). Based on these scores, nine mutations were selected for predicted 




Fig. 1  Mutations in the interface between the B7 TCR and Tax11-19/HLA-A2 are scored poorly 
with the Rosetta interface and ZAFFI 1.1 functions. (a) Structural overview of the B7 TCR–
pMHC complex. (b) Score vs. experimental ΔΔG° for point mutations modeled with Rosetta and 
scored with the Rosetta interface function. The best fit line and correlation coefficient is 
indicated. (c) As with panel b, scored with the ZAFFI 1.1 function (Haidar et al., 2009; Pierce et 
al., 2014). 
 
We performed mutagenesis using soluble B7 gene constructs, expressed and purified the mutant 
and wild-type proteins, and measured their binding affinities toward Tax11–19/HLA-A2 using 
surface plasmon resonance (Table S1 and Fig. S1). Three of the mutations (S27αM, S50αY, 
G99βY) led to moderately enhanced affinity towards Tax11–19/HLA-A2, although the remaining 
six mutations weakened affinity or led to no detectable binding. Including four additional B7 
mutations studied previously (Piepenbrink et al., 2013), the correlation between the predicted 
and experimental change in binding energy was low with the Rosetta interface score function 
(R = 0.21; Fig. Fig.1b).1b). Utilizing the ZAFFI score function first developed for the A6 TCR 
and refined with the DMF5 TCR (Haidar et al., 2009; Pierce et al., 2014) led to an improved but 
still weak correlation (R = 0.47; Fig. Fig.1c).1c). Thus, the TCR design approach developed for 
the A6 TCR and later applied to DMF5 performs poorly with the B7 TCR.  
Collection of new data to train a score function for HLA-A2-restricted TCRs 
In light of the low correlations between prediction and experiment with the B7 TCR, we aimed 
to develop a more generalizable framework for modeling and predicting point mutations across 
multiple TCR–pMHC interfaces. We collected 96 independent ΔΔG° values resulting from 
single amino acid mutations from four TCR–pMHC interfaces (A6-Tax11–19/HLA-A2; B7-Tax11–
19/HLA-A2; DMF5-MART127–35/HLA-A2; and DMF5-MART126(27L)–35/HLA-A2). This data 
originated from our previously published structure-guided design efforts with the A6 and DMF5 
TCRs (Haidar et al., 2009; Pierce et al., 2014) as well as our recent double mutant cycle 
deconstruction of the A6 interface (Piepenbrink et al., 2013). We also included the additional 
data with B7 described above, and performed new binding measurements in the DMF5-
MART126(27L)–35/HLA-A2 interface (Table S1 and Fig. S1). We restricted the dataset to high 
quality measurements with low experimental error (< 0.5 kcal/mol). 
The point mutations in our dataset covered a broad range of mutation types as described in Table 
S2. The ΔΔG° values ranged from −1.8 to 2.8 kcal/mol and were approximately normal in 
distribution (Fig. (Fig.2a).2a). The median ΔΔG° value of the selected dataset was 0.5 kcal/mol 
with a standard deviation of 1.1 kcal/mol. When comparing the 29 mutations that improved 
binding, it became evident the majority of affinity-enhancing mutations resulted from 





Fig. 2 Experimental ΔΔG° values of TCR point mutations are normal in distribution and affinity-
enhancing mutations are predominantly hydrophobic or amphipathic. (a) The 96 point mutations 
collected in different TCR–pMHC interfaces were approximately normal in distribution with a 
median ΔΔG° value of 0.5 kcal/mol and a standard deviation of 1.1 kcal/mol. (b) Sequence logos 
of the 29 mutations that improved binding (ΔΔG° < 0). 
Development of a generalized TCR–pMHC scoring function 
We next developed computational structural models of all 96 point mutations for training 
generalized TCR prediction models. We extended our strategy by adapting techniques for 
modeling the effects of interface mutations shown to be successful in recent community-wide 
assessments. Mutations were modeled with the standard Talaris2013 score function allowing for 
off-rotamer sampling and limited backbone flexibility in the CDR loops (Leaver-Fay et al., 
2013; Moretti et al., 2013). Additionally, side chains of residues within a 10 Å sphere of any 
CDR loop residue were repacked in response to each mutation and resulting CDR loop 
movements. Each point mutation was modeled in triplicate and scores averaged for further 
analysis. Analysis of the mutation models identified one with an anomalously high repulsive 
clash score and another where a residue was forced into an unusual high energy rotamer. Both of 
these mutations were excluded from further training and comparisons, leaving a dataset of 94 
point mutations and their structural models. 
To develop a generalizable TCR scoring function, we considered 16 full-atom Rosetta terms 
commonly used for protein design and structure prediction (Leaver-Fay et al., 2013; Moretti et 
al., 2013). Using the Rosetta terms as predictor variables and experimental binding energies of 
the dataset described above as the response variable, we used multi-linear regression to 
parameterize a starting score function for estimating the effect of the various point mutations on 
ΔΔG°. The most significant contributors to the model (P < 0.05) described van der Waals 
attractive forces and solvation effects. However, the correlation between binding score and 
ΔΔG° remained low (R = 0.43; Fig. Fig.3a).3a). Thus we did not explore removing insignificant 




Fig. 3  Relative TCR–pMHC complex scores correlate better with affinity than binding scores. 
(a) Scores vs. experimental ∆∆G° for modeled point mutations. Scores were determined by 
scoring each complex and two free proteins (i.e. binding score = scorecomplex − (scoreTCR + 
scorepMHC)). The wild-type ‘binding score’ was then subtracted from each mutant binding score. 
After parameterization of Rosetta structural terms, relative binding scores were plotted vs. 
experimental ΔΔG°. (b) As with panel a, but scores determined and parameterized by scoring 
only the wild-type and each mutant complex, yielding ‘complex scores’ as described in the text. 
Ideally, binding energy calculations would utilize structural information for both the free and 
bound molecules (Kortemme and Baker, 2002; Vreven et al., 2012). However, structures of free 
TCRs and pMHCs can vary between free and bound states (Armstrong et al., 2008), and the 
large surface areas of receptor and ligand binding sites possess significant conformational 
degrees of freedom. We thus focused only on relative effects by scoring only TCR–pMHC 
complexes, rather than scoring the complex and the two free proteins as described above. We 
refer to the difference in scores between wild type and mutant complexes as ‘complex scores’. 
This approach comes with a limitation in that complex scores do not account for energies in the 
free TCR associated with making the mutation (i.e. the ΔG° for TCR WT ↔ TCR mutant). 
Ideally these would be subtracted when examining the impact of a mutation on binding. There 
are two potentially significant consequences to this. First, an improved complex score could arise 
solely due to improved contacts within the TCR (i.e better TCR stability). We minimized the 
impact of this by focusing on sites that are in proximity to the ligand and thus more likely to 
influence binding. Second, any effects on binding stemming from conformational changes in the 
free TCR will be ignored. 
Using the same 16 full-atom Rosetta terms, a multi-linear regression of complex scores vs. ΔΔG° 
yielded an improved function (R = 0.66 for complex scores, vs. R = 0.43 for binding scores; Fig. 
Fig.3b).3b). Despite the theoretical limitations noted above, complex scores are therefore more 
applicable for our framework and were used for all further calculations. The improvement using 
complex scores may reveal underlying limitations in the energy function terms and/or limitations 
in recapitulating conformational differences between free and bound TCRs as noted above, 
leading to inaccuracies when ‘binding scores’ are computed. The inherently weak affinities and 
correspondingly poor quality of TCR–pMHC interfaces (compared, e.g. to high affinity 
antibody-antigen interfaces) could also contribute to why complex scores outperform binding 
scores. 
Refinement of the regression model to include flexibility and validation of terms 
Although utilization of complex scores improved the correlation between prediction and 
experiment, we sought to identify additional predictors of TCR binding affinity that might 
further improve performance. One of the differences between TCRs is their degree of binding 
loop flexibility, particularly for the hypervariable CDR3α and CDR3β loops (Scott et al., 2011). 
Although various methods for conformational sampling such as stochastic loop perturbations or 
generation of structural ensembles exist (Feixas et al., 2014; Sinko et al., 2013; Tuffery and 
Derreumaux, 2012), these are computationally expensive. To more simply address the impacts of 
TCR loop flexibility, we considered descriptors from molecular dynamics (MD) simulations of 
the free and bound TCRs. We recently described a comprehensive MD study of the free and 
bound A6 and DMF5 TCRs (Ayres et al., 2016) using an experimentally benchmarked 
simulation methodology (Scott et al., 2011, Scott et al., 2012). We performed similar simulations 
on the free and bound B7 TCR. From these simulations root mean square (RMS) fluctuations for 
each α carbon were determined along with Cα-Cβ (Cα-H for glycine) and Cα-C order parameters 
to quantify nanosecond timescale backbone flexibility (Fig. S2). Due to the time that would be 
required to simulate dozens or hundreds of mutations, only the wild-type TCRs and their 
complexes were simulated. Fluctuation values and order parameters were then treated as 
‘positional modifiers’ for each amino acid position, biasing positions for design based on their 
relative flexibility in the wild-type free and bound structures. Although necessary for throughput, 
this approach makes the limiting assumption that any given mutation does not impact backbone 
flexibility on the nanosecond timescale. 
To determine if inclusion of RMS fluctuations and/or order parameters could lead to an 
improved scoring function, we included these six terms along with the 16 full-atom Rosetta 
terms in a multi-linear regression of complex scores vs. ΔΔG°, coupled with a stepwise 
elimination protocol (Hocking, 1976). This fit identified six significant (P < 0.05) features: four 
structural terms (van der Waals attractive and repulsive forces, solvation energies and sidechain 
hydrogen bonding) and two flexibility terms (RMS fluctuations for α carbons of the free and 
bound structures). A structural term weighting Ramachandran angle propensities was borderline 
significant (P = 0.11), but was retained to help identify and exclude structural models with 
residues forced into unrealistic conformations. 
The regression models estimated the weights of the RMS fluctuation features to be negative, 
suggesting flexible positions are more favorable to target for design (although mobility in the 
complex was weighted more heavily as discussed below). To critically examine the significance 
of this determination, models with and without the fluctuation terms in addition to the five 
Rosetta terms were generated and compared. Akaike information criterion (AIC) (Akaike, 1998) 
found the incorporation of features describing flexibility resulted in a 99.8% likelihood of a 
superior prediction model. Bayesian information criterion (BIC) (Kass and Raftery, 1995) more 
strongly penalized additional terms, yet also indicated that inclusion of the fluctuation terms 
improved the regression model beyond random chance (Table (TableII).  
Table I. 
Inclusion of RMS fluctuations improves the score function regression model 
Criteria RMSF excluded RMSF included 
R  0.63 0.71 
P-value 7.9 × 10−9 9.0 × 10−11 
AIC 239.2 226.8 
BIC 254.4 246.2 
Finally, a k-fold cross validation (k = 10) (Arlot and Celisse, 2010) was used to validate and 
estimate overall predictive performance. From this analysis, the RMS error (reflecting the 
difference between experimental and predicted ΔΔG° values) was estimated as 0.81 kcal/mol, 
with an impressive correlation of 0.71 (Fig. (Fig.4a;4a; note this correlation includes accounting 
for structural water as described below). For comparison, our previous approach with the Rosetta 
interface score function yielded a correlation of only 0.16 (Fig. (Fig.4b),4b), and a recent 
analysis of protein design approaches estimated an average error of 1.2 kcal/mol for protein–
protein interactions (Potapov et al., 2009). The terms and weights for the final regression model, 




Fig. 4  The TR3 score function outperforms our previous TCR design methodology. (a) Complex 
score vs. experimental ΔΔG° for 94 point mutations modeled with Rosetta and scored with the 
TR3 function. The best fit line, 95% confidence interval, and correlation coefficient is indicated. 
(b) Performance of our previous methodology applied to the same data. An off-scale prediction 
score of 26 (DMF5 G28αL) is denoted by a black arrow and the best fit line and correlation are 
indicated. 
Table II. 
Terms and their statistics in the TR3 score function 
Term Weight Errora P-valueb 
Intercept 2.29 0.35 <0.001 
Fa_atr 0.21 0.03 <0.001 
Fa_rep 0.05 0.01 0.005 
Fa_sol 0.18 0.08 <0.001 
Hbond_sc 0.34 0.09 0.008 
Rama 0.12 0.05 0.119 
RMSF_bound −0.82 0.30 0.049 
RMSF_free −0.36 0.10 0.003 
Estimated error: 0.81 kcal/molc 
aDetermined as 1.96 standard deviations of k-fold cross-validation weights. 
bP-value for the F statistic of the hypotheses test that the corresponding coefficient is equal to 
zero.  
cAverage test RMS error from k-fold cross validation. 
 
Accounting for energetically significant structural water improves predictions 
Rosetta utilizes an implicit solvation model to estimate solvation energies associated with bulk 
water (Lazaridis and Karplus, 1999). However, TCR–pMHC interfaces are large and buried 
water molecules are often observed crystallographically. In some instances these structural 
waters play key roles in the interface that would not be captured with an implicit solvation model 
(Jiang et al., 2005). Indeed, many predicted mutations which filled the void of an interfacial 
water molecule in the interface with the DMF5 TCR resulted in a falsely favorable score. For 
example, Ser99 in the DMF5 β chain contacts the peptide, but is also involved in a complex 
water-mediated hydrogen bond network linking the peptide to the TCR (Fig. (Fig.5a).5a). The 
predicted impacts of mutations at this position did not correlate well with experiment (Fig. 
(Fig.5b),5b), consistent with a determination that this water molecule is structurally and 
energetically significant. To directly account for it, the buried water in the DMF5 interface was 
docked into its corresponding pocket and treated explicitly in modeling and scoring. This 
improved the agreement between prediction and experiment for Ser99β point mutations without 
altering the predictions for distant residues (Fig. (Fig.5c).5c). Further design efforts incorporated 
this technique when buried water molecules were observed crystallographically in the interface 




Fig. 5  Accounting for buried structural water improves predictions. (a) A buried water molecule 
observed crystallographically in the DMF5-MART126(27L)-35/HLA-A2 interface forms multiple 
electrostatic interactions between the TCR and peptide. The sidechain of Ser99 of the DMF5 β 
chain is indicated. (b) The correlation between prediction and experiment for models of DMF5 
point mutants scored with TR3 is 0.63 when the buried water molecule is ignored. Five 
mutations at position 99β are indicated and are responsible for the low correlations. (c) The 
correlation between prediction and experiment for DMF5 point mutants improves to 0.80 when 
the buried water molecule is treated explicitly. The predicted effects of the five mutations at 
position 99β agree better with experiment as shown. 
 
Validation with new TCR mutations and combinations to further modulate 
affinity 
We next collected additional data to assess the performance of our new framework on mutations 
not used in training. We screened for new mutations in the interfaces with the DMF5 and B7 
TCRs (DMF5-MART126(27L)–35/HLA-A2 and B7-Tax11–19/HLA-A2). To emphasize peptide 
specificity, only positions with a center of mass within 10 Å of a peptide heavy atom were 
selected for design. A total of 18 sites in both DMF5 and B7 were modeled and scored with all 
20 amino acids (684 point mutations in total and 36 wild-type controls). As expected, most 
mutations were predicted to have deleterious effects on binding. However, several mutations 
were predicted to enhance affinity, most at sites where mutations have previously been shown to 
favorably impact binding (Table S1). The two predicted to be most favorable (G99βW for B7; 
D26αF for DMF5) were both generated, and the impact on binding assessed experimentally. 
Both mutations improved binding as predicted. The ΔΔG° for G99βW in B7 was −0.5 kcal/mol; 
for D26αF in DMF5 it was −0.4 kcal/mol. The value for D26αF was less than observed 
previously with tyrosine or tryptophan at this position (−1.8 and −1.6 kcal/mol, respectively), 
suggesting that the amphipathic character of tyrosine and tryptophan may be advantageous for 
enhancing TCR affinity as discussed below. 
Our previous designs for the A6 and DMF5 TCRs combined multiple mutations to generate 
molecules which bound in the nanomolar range (Haidar et al., 2009; Pierce et al., 2014). The 
approximate additive effects of mutations in both interfaces were captured by our new 
framework with the TR3 score function after averaging the RMSF positional values of each of 
the mutations. To ask if our new framework also allowed for this in another TCR, we combined 
the S27αM and G99βY mutations in the B7 receptor, which together improved the B7 affinity 
for Tax11–19/HLA-A2 7-fold, from 1.5 μM to 220 nM (Fig. (Fig.6).6). These mutations are ~27 Å 
apart, and were correctly predicted to be additive when combined (ΔΔG° = −1.2 kcal/mol, 




Fig. 6 Combining two computationally designed B7 mutations yields nanomolar binding affinity. 
(a) Combining the S27αM and G99βY mutations in the B7 TCR improves binding to Tax11-
19/HLA-A2 7-fold, from 1.5 µM to 220 nM. (b) The sites of the S27αM and G99βY mutations in 
the B7 TCR are separated by ~27 Å and are predicted to improve affinity independently through 
improved van der Waals interactions with the pMHC. 
 
To investigate broader applicability, mutations in another TCR not used in training were 
modeled and scored. The DMF4 TCR also recognizes MART1 antigens presented by HLA-A2, 
but utilizes different α and β chains than DMF5, A6 and B7 (Borbulevych et al., 2011; Johnson 
et al., 2009). As performed with the A6, B7 and DMF5 TCRs, MD simulations of the free wild-
type DMF4 TCR and its complex with MART126(27L)–35/HLA-A2 were performed and used 
along with Rosetta to simulate 960 structures (19 mutations at 48 sites, and 48 wild-type 
controls) in the DMF4-MART126(27L)−35/HLA-A2 interface. Several mutations in the α chain 
were favorably ranked based on their ability to fill an interfacial void near the N-terminus of the 
peptide. Three of these mutations were selected for experimental investigation (S26αW, N29αW 
and T92αW). Although the N29αW mutation was of particular interest as it provided another 
opportunity to investigate a structural water, this mutant could not be folded from inclusion 
bodies. This left two mutations for experimental testing. As predicted, both of these enhanced 
DMF4 binding affinity, with ΔΔG° values of −0.4 and −0.9 kcal/mol (Table S1). These 
mutations were also predicted and found to be additive when combined: together the S26αW and 
T92αW mutations improved the affinity of the DMF4 TCR 10-fold, from 60 to 6 µM (ΔΔG° of 
−1.4 kcal/mol). 
Overall, when applied to data outside of our training set, our new modeling and scoring 
procedure recapitulated the effects of multiple mutations in the B7, DMF5 and DMF4 TCRs and 
permitted the identification of new affinity-enhancing mutations in all three receptors. The RMS 
error between predicted and experimentally determined impacts on binding was 1.5 kcal/mol, 
higher than observed with training and cross-validation but still lower than observed with our 




Fig. 7  Performance of our improved framework on new TCR mutations, HLA-A2 mutations and 
peptide variations. (a) All point mutation data examined in evaluating our new approach, 
including TCR, peptide and HLA-A2 data, plotted together, excluding data used in training. The 
overall correlation between prediction and experiment is 0.86. (b) The predicted effects of 
MART126(27L)-35 peptide substitutions on the binding of DMF5 to MART126(27L)–35/HLA-A2 
indicate amino acids that are more tolerating of or more sensitive to substitutions. Position 6 near 
the center of the peptide is particularly sensitive. Each segment of the plot shows the complex 
scores for all 20 amino acids substituted at the indicated position. Solid lines and numbers in 
each segment show the average scores for all 20 amino acids at that position. (c) Performance is 
more limited on a system involving a more diverse, non-HLA-A2 restricted TCR. The impact of 
mutations in the LC13 TCR with FLR/HLA-B8 are predicted with a correlation coefficient of 
0.60 (ΔΔG° values of mutations with no detectable binding were reported previously as 1.6 
kcal/mol) (Borg et al., 2005). 
 
Including HLA-A2 mutations in validation 
αβ TCRs show MHC restriction, i.e. they recognize peptides only when presented by MHC 
proteins (Zinkernagel and Doherty, 1974). Many studies have examined the effects of mutations 
in the α helices of MHC binding groove as a means to determine energetically significant 
positions that might guide restriction, including a recent comprehensive analysis of the binding 
of A6 TCR to the Tax11–19/HLA-A2 complex. Of nine published mutations, eight weakened 
affinity and one enhanced affinity (Piepenbrink et al., 2013). To recapitulate this data in silico, 
we modeled the impact of mutations in HLA-A2 on the binding of A6 to Tax11–19/HLA-A2, 
incorporating free and bound flexibility through MD simulations as described above. The effects 
of these mutations were well captured, with RMS error between prediction and experiment of 1.0 
kcal/mol (Fig. (Fig.7a,7a, green points). Thus our new framework is applicable not only to 
TCRs, but can predict the energetics associated with mutations in the HLA-A2 side of the 
interface as well. 
Computational scanning of peptide variants 
TCRs are broadly cross-reactive and recognize a multitude of antigenic peptides, a requirement 
of the fixed size of the T-cell repertoire (Mason, 1998). Additionally, altering TCR binding by 
changing peptide sequence is another approach for modulating TCR binding and immune 
responses (McMahan and Slansky, 2007; Piepenbrink et al., 2009). Quantitative data for how 
eight substitutions in the Tax11–19 peptide impact the binding of the A6 TCR is available (Davis-
Harrison et al., 2007; Piepenbrink et al., 2013), and we collected new alanine scanning data for 
recognition of four more Tax11–19 variants by B7 (Table S1). As with the HLA-A2 mutations 
above, we used our new modeling and scoring approach to assess how these peptide variants 
impact recognition by A6 and B7. The impacts on binding ΔΔG° were recapitulated well, with 
an RMS error of 0.9 kcal/mol (Fig. (Fig.7a,7a, yellow points). 
To further demonstrate the utility of our approach for assessing peptide variations, residues in the 
MART126(27L)–35 peptide were computationally varied to cover all 20 amino acids, and, after 
completing a MD simulation of the MART126(27L)–35/HLA-A2 complex, scored for impact on 
DMF5 binding. All peptide substitutions were predicted to be unfavorable, although mutations at 
the P3 and P6 positions were predicted to have the most dramatic impacts (Fig. (Fig.7b).7b). 
This outcome is consistent with recent findings on TCR specificity, which suggest the existence 
of peptide ‘hotspots’ of reduced structural and chemical diversity, outside of which greater 
variation is permitted (Adams et al., 2016). 
Next, eight MART126(27L)–35 peptide variants with a broad range of complex scores were selected 
for experimental testing with DMF5 (Table S1). We also examined a peptide with a non-standard 
sarcosine (N-methyl glycine) substituted for Gly6 of the peptide to help test the implications of 
treating structured water explicitly in the DMF5 interface as discussed above and shown in Fig. 
Fig.5.5. Overall, there was a good correlation between ΔΔG° and binding score for the nine 
MART126(27L)–35 peptide variants explored experimentally, with experiment and prediction 
differing with an RMS error of 0.9 kcal/mol (Fig. (Fig.7a,7a, blue points). The experiments with 
the sarcosine-modified peptide led to improved binding as predicted, leading to a 3-fold affinity 
enhancement in affinity (ΔΔG° of −0.6 kcal/mol). The affinity enhancement is attributable to the 
increased van der Waals interactions to Thr102 of the TCR while maintaining the solvated state 
of polar atoms in the surrounding pocket. 
Overall performance and exploration of an even more diverse, non-HLA-A2 
interface 
To explore the overall performance of our new approach, we examined the new TCR mutations, 
HLA-A2 mutations and peptide variants described above together as one large test set. These 
amounted to 40 independent ΔΔG° measurements distinct from the training set from five 
different TCR–pMHC interfaces. We also included the double mutants in the DMF5, B7 and A6 
TCRs. Altogether, performance was excellent, with predicted and experimental impacts on 
binding agreeing with an impressive correlation coefficient of 0.86 and a RMS error of 1.1 
kcal/mol, spanning a large range of ~7 kcal/mol in binding free energy (Fig. (Fig.7a,7a, all 
points). Complex scores again showed improved performance over binding scores, as scoring the 
40 test set mutations using binding scores yielded a weaker correlation coefficient (R = 0.66) and 
larger RMS error (2.8 kcal/mol) (Fig. S3). 
The systems used in development and testing all involved the class I MHC protein HLA-A2. To 
explore how our new framework performed when additional diversity was included, we used it 
to assess the impact of mutations between the interface of the LC13 TCR and the class I MHC 
protein HLA-B:08:01 (HLA-B8) presenting the FLR peptide (sequence FLRGRAYGL). The 
structure of the LC13-FLR/HLA-B8 complex has been determined, as have ΔΔG° values for 39 
alanine or glycine mutations in the various LC13 CDR loops (Borg et al., 2005). After 
completing MD simulations of LC13 and its complex, we applied our approach to this dataset, 
recapitulating the effects of these mutations with an overall correlation of 0.60 and an RMS error 
of 1.0 kcal/mol (Fig. (Fig.7c).7c). While errors are still within the range obtained with our 
previous methodology (Pierce et al., 2014), the correlation is weaker than what we achieved with 
HLA-A2-restricted systems. 
There are at least two possible reasons for the weaker performance with the LC13 TCR. First, 
many of the 39 mutations in the LC13 interface result in very weak or no detectable binding, 
with ΔΔG° values reported simply as above an upper limit of 1.6 kcal/mol (corresponding to a 
15-fold weakening of affinity). The limited accuracy of these measurements will affect the 
correlation between prediction and experiment. As evidence of this, binary metrics demonstrated 
good predictive performance when separating affinity increasing mutations from affinity 
decreasing mutations (ROC AUC = 0.84; Fig. S4). Second, our reliance on HLA-A2-restricted 
systems in parameterization of the new TR3 score function could result in an inherent bias. 
HLA-A2 and HLA-B8 differ by 42 amino acids, 32 of which are in the peptide binding domain 
(Robinson et al., 2011). In addition to different energetic contributions, these differences could 




TCRs have emerged as a new class of immunological therapeutics, most prominently for cancer, 
where they are the key components of new cellular immunotherapies as well as soluble biologics 
(Oates and Jakobsen, 2013; Restifo et al., 2012). There is significant interest in enhancing TCR 
affinity to improve antigen sensitivity, and accordingly, numerous high affinity TCRs have been 
generated. Although T-cell potency has been shown to improve with affinity, questions remain 
about the existence of optimal affinity windows or thresholds and the merits of large vs. 
incremental improvements in binding affinity (Stone and Kranz, 2013). Additionally, following 
adverse events in clinical trials (Morgan et al., 2013; Parkhurst et al., 2011), there is a growing 
recognition of the importance of evaluating and controlling specificity in affinity-enhanced or 
otherwise modified TCRs. 
In principle, structure-guided computational design offers the potential for fine manipulation of 
TCR binding properties. Structure-guided design has been used to generate a small number of 
high affinity TCRs, as well as manipulate binding specificity (Haidar et al., 2009; Malecek et al., 
2014; Pierce et al., 2014; Zoete et al., 2013). However, although the TCR–pMHC structural 
database has grown significantly in recent years, wide-scale application of structure-guided TCR 
design is hindered by several complexities. These include the complex architecture of the TCR–
pMHC interface (Baker et al., 2012; Rossjohn et al., 2015), as well as the varying degrees of 
diversity and molecular flexibility in both receptor and ligand (Borbulevych et al., 2009; 
Insaidoo et al., 2011; Scott et al., 2011). We demonstrated the limited applicability of current 
TCR design approaches here by showing that our prior approach used to successfully engineer 
the clinically relevant DMF5 TCR performed poorly when applied to the unrelated B7 TCR. 
To generate an improved framework for structure-guided TCR design, we assembled a large 
database of mutations from four TCR–pMHC interfaces and used this in developing a new, 
‘general purpose’ approach to TCR design, including a novel score function. Similar to other 
score functions trained to predict binding affinity (Kortemme and Baker, 2002), the results 
heavily weighted van der Waals attractive forces and solvation and dampened repulsive terms. 
We also accounted for molecular flexibility via a novel cost-effective approach. For data in the 
training set we were able to achieve a correlation between predicted effect on binding and 
experimental ΔΔG° of 0.71. When applied to new data from multiple TCRs, HLA-A2 and 
peptides, we obtained an impressive correlation of 0.86 and low RMS error of 1.1 kcal/mol, 
which is near the expected upper limit due to error in experimental data (Potapov et al., 2009). 
As with other studies, the slope of predicted vs. experimental ΔΔG° was <1, indicating that 
impacts on binding affinity are typically under-estimated, giving some indications of ways to 
improve. The potential for further improvements is also found with the better performance 
observed with complex vs. binding scores, despite the theoretical limitations associated with 
complex scores. 
Accounting for flexibility is an important aspect of our improved framework, as varying degrees 
of CDR loop, MHC and peptide flexibility is a characteristic feature of TCRs and pMHC 
complexes (Borbulevych et al., 2009; Insaidoo et al., 2011; Scott et al., 2011). As with other 
efforts in protein design, we relied on MD simulations to incorporate flexibility. However, as 
opposed to simulating structures to identify alternate configurations or generate structural 
ensembles (Feixas et al., 2014; Sinko et al., 2013; Tuffery and Derreumaux, 2012), we added 
‘positional modifiers’ that report on amino-acid level motional properties as terms in the score 
function. We chose this approach as it greatly simplifies the treatment of flexibility, requiring 
only single MD trajectories for the free wild-type TCR and the TCR–pMHC complex. Of the 
properties considered, Cα RMS fluctuations were most significant and were incorporated into the 
final function. The weights for these terms were negative, indicating that more flexible positions 
are more favorable for design. There is some anecdotal evidence to support this: in the A6 TCR, 
the hypervariable CDR3β loop is by far the most mobile, and multiple mutations within this loop 
improve A6 binding (Haidar et al., 2014; Li et al., 2005; Scott et al., 2011). This could reflect a 
form of the ‘fly-casting’ effect, in which mobile sites in a receptor are more adept at finding 
compatible partner sites in a ligand (Shoemaker et al., 2000). Interestingly, the flexibility 
weights were larger for residues in the bound state. While residual mobility in TCR–pMHC 
interfaces has been observed and this term could be accounting for this (Hawse et al., 2014; 
Reboul et al., 2012), it is also possible that in the complex this term helps overcome limited 
conformational sampling in modeling. Further work is needed to explore this, along with 
whether using longer or additional MD simulations can yield further improvements, at the 
expense of throughput. 
Solvent considerations can be important in structure-guided design, as buried water molecules 
can play critical roles in protein binding (Janin, 1999; Rodier et al., 2005). As seen in other 
systems (de Graaf et al., 2005), we demonstrate that explicitly modeling water in TCR interfaces 
can improve predictions. This was most useful for the DMF5 TCR, although buried waters were 
incorporated when modeling the DMF4 and LC13 interfaces as well (chosen in these cases 
because they were buried in the interface and participated in multiple hydrogen bonds with the 
TCR, peptide or MHC). Because we relied on crystallographically observed water, there is a 
corresponding demand on the resolution and quality of the original crystal structure. As TCR–
pMHC interfaces may be poorly packed and crystallographic resolutions low, incorporation of 
approaches to predict the location of water molecules not observed crystallographically could 
lead to further improvements (Bui et al., 2007; Jiang et al., 2005). 
Our improved framework for TCR design permitted the identification of new affinity-enhancing 
mutations in multiple interfaces, including the DMF4 TCR which was not used in training and 
uses different Vα and Vβ genes than those in the training set (Borbulevych et al., 2011; Johnson 
et al., 2009). The enhancements to affinity are relatively modest, but as noted above fine control 
may be most desirable when manipulating TCR affinity. Additionally, when combined these 
mutations can yield larger improvements, as shown for the B7, A6, DMF4 and DMF5 TCRs. 
Our approach also accounted for the relative effects of alanine and glycine mutations in another 
TCR, LC13, although the poorer performance with this receptor suggests that application to class 
I MHC proteins other than HLA-A2 (such as the HLA-B8 allele recognized by LC13) could 
require additional training outside of HLA-A2 systems to improve generality. By extension, we 
can expect that application towards other MHC proteins, particularly class II or nonclassical 
MHC proteins, will also require further effort. 
Mutations which enhanced affinity tended to be (although were not exclusively) those that 
replaced small polar or charged residues with large hydrophobic or amphipathic amino acids. 
The significance of this is unclear; this was seen in our training data as well as new mutations. 
Increasing buried hydrophobic surface area is a well-known strategy for enhancing binding, and 
the rigid, bulky and amphipathic nature of tyrosine and tryptophan provide structural and 
chemical utility (Koide and Sidhu, 2009). Highly antigenic peptides have a tendency to be 
enriched in hydrophobic amino acids in TCR contact sites (Chowell et al., 2015), potentially 
indicating that such amino acids are indeed optimal for enhancing TCR affinity. 
What do these results indicate about introducing charged or polar amino acids? While 
electrostatic interactions can contribute to specificity, their contributions to affinity can vary due 
to high desolvation penalties (Bosshard et al., 2004; Hendsch and Tidor, 1994). Additionally, 
electrostatic interactions have strict geometrical dependences. Due to these complexities, protein 
design algorithms are recognized to have limited success modeling electrostatics (Fleishman et 
al., 2011; Procko et al., 2013; Stranges and Kuhlman, 2013). Thus introduction of charged or 
polar interactions may be unintentionally disfavored during design. Overcoming this potential 
limitation is important, as an over-reliance on select amino acids limits applicability. Further, 
accurately accounting for electrostatic effects could provide another means to selectively 
engineer TCR specificity, irrespective of their impacts on binding affinity (Blevins et al., 2016; 
Stadinski et al., 2016). 
The availability of polar/charged mutations that improve TCR binding will be helpful in further 
assessing and improving our design framework. Molecular evolution experiments can provide 
such data, although because multiple mutations are often found in affinity-matured molecules, 
identifying the impact of individual mutations can be difficult. Perhaps a more promising source 
for such data could be deep mutational scanning experiments, which sample the effects of every 
amino acid at multiple positions in one experiment (Fowler and Fields, 2014; Whitehead et al., 
2012). Our recent deep mutational scanning experiments with the A6 and variant TCRs provide 
several promising examples of polar/charged mutations that appear to favorably impact binding 
(Harris et al., 2016), and careful analysis of these will be helpful. 
Lastly, our approach was also able to account for the effects of mutations in the HLA-A2 protein 
as well as peptide substitutions. This raises the possibility of using computational design not only 
for engineering TCRs to modulate their binding properties, but also ligands with enhanced 
affinity for select TCRs. Such an approach has been proposed as a novel means for peptide-based 
vaccine design (McMahan and Slansky, 2007; Piepenbrink et al., 2009), and could be useful in 
the development of new T-cell detection or imaging reagents. Additionally, the capacity to 
accurately score peptide variants could allow for computationally assessing the cross-reactivity 
of TCRs or the reactivities of peptide sets. This could prove useful for predicting and controlling 
off target toxicity for TCRs used clinically or identifying reactive self-antigens in autoimmunity, 
transplantation or vaccination. 
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Figure S2. Root mean square fluctuations from MD simulations of free and bound TCRs and pMHC complexes. 
For TCRs, shaded boxes indicate the locations and values of the six CDR loops. Data for the A6 and B7 TCRs 
is from Ayres et al., 2016.
Figure S1. Representative TCR-pMHC SPR binding data for experiments shown in Table S1.
























Figure S4. Receiver operating characteristic (ROC) curve for predictions in the LC13 system. The area under the 
curve is 0.84, indicating good predictive performance when separating affinity increasing mutations from affinity 
decreasing mutations
Figure S3. Performance of our improved framework on new TCR mutations, HLA-A2 mutations, and peptide variations 
when evaluated using binding rather than complex scores. All point mutation data examined in evaluating our new 
framework, including TCR, peptide, and HLA-A2 data, are plotted together, excluding data used in training. The overall 
correlation between prediction and experiment with binding scores is 0.66, compared to 0.86 when using complex 
scores (compare with Fig. 7a).
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HLA-A2 Tax11-19 MART126(27L)-35 TCRs
Table S1. New binding data for TCR mutations and peptide substitutions in the B7, DMF5, and DMF4 
TCR-pMHC interfaces 
TCR Peptidea TCR mutation or peptide substitution ΔΔG° (kcal/mol) Error (kcal/mol) 
B7 Tax S27αM -0.43 0.08 
B7 Tax D30αQ >2 NDb 
B7 Tax S50αY -0.73 0.09 
B7 Tax M93αE >2 ND 
B7 Tax M93αQ 1.94 0.1 
B7 Tax Q102αW 0.56 0.14 
B7 Tax P97βW >2 ND 
B7 Tax G98βF 0.82 0.09 
B7 Tax G99βY -0.39 0.11 
B7 Tax G99βW -0.47 0.08 
B7 Tax S27αM/G99βY -1.15 0.1 
B7 Tax pF3A 2.7 0.02 
B7 Tax pY5A 3.28 0.11 
B7 Tax pY5F 0.55 0.04 
B7 Tax pY8A 2.76 0.07 
DMF5 ELA D26αF -0.43 0.1 
DMF5 ELA R27αF -0.3 0.13 
DMF5 ELA K96αW -0.65 0.12 
DMF5 ELA T54αI 0.33 0.12 
DMF5 ELA S99βF >2 ND 
DMF5 ELA S99βH 1.48 0.11 
DMF5 ELA S99βI 1.36 0.09 
DMF5 ELA S99βL 2.27 0.03 
DMF5 ELA S99βT 0.4 0.13 
DMF5 ELA pE1A 0.06 0.19 
DMF5 ELA pE1D 1.3 0.26 
DMF5 ELA pE1F 2.26 0.06 
DMF5 ELA pE1Q 1.0 0.03 
DMF5 ELA pI5E 3.07 0.18 
DMF5 ELA pG6-Sarc -0.58 0.07 
DMF5 ELA pL8A >3 ND 
DMF5 ELA pT9A 1.6 0.03 
DMF5 ELA pT9W >3 ND 
DMF4 ELA S26αW -0.63 0.04 
DMF4 ELA T92αW -0.38 0.06 
 
aTax = HTLV Tax11-19 (LLFGYPVYV); ELA = MART-126(27L)-35 (ELAGIGILTV) 
bND =  not determined 
Table S2. Descriptive breakdown of training set data 
Total mutations in training set 94  
Polar/charged WT residues 56 (60%) 
Polar/charged mutant residues 24 (26%) 
Mutations with polar/charged WT & mutant residues 11 (12%) 
Large hydrophobic/aromatic WT residues1 14 (16%) 
Large hydrophobic/aromatic mutant residue 41 (44%) 
Mutations with large hydrophobic/aromatic WT & mutant residues 7 (7%) 
Alanine mutations2 22 (23%) 
Alanine mutations with large/hydrophobic WT residues 5 (5%) 
1Large hydrophobic/aromatic residues defined as Y/W/L/I/F/M 
2Excluding mutations with glycine WT residues 
  
 
